Innovation Dermatologics, Inc.
IDI is a start-up specialty biopharmaceutical company focused on identification and development of innovative dermatologic therapeutics
IDI is a start-up specialty biopharmaceutical company. The lead indication for IDI is basal cell carcinoma (BCC), the most common skin cancer and also the most common among all cancers. The drug development program involves repurposing of an oral inhibitor of the Hedgehog biologic pathway, a key pathway exhibiting abnormal regulation in various cancers, for local administration.